Novel therapies for HFmrEF and HFpEF aim to improve symptom management and patient outcomes, addressing current treatment limitations. Emerging treatments could reduce hospitalization rates and ...

mean age 68 years [7], 22% women, and 83% white race or ethnicity), and 9446 patients with HFmrEF or HFpEF from TOPCAT (3445 patients, mean age 68 years [9], 52% women, and 89% white race or ethnicity ...

Steroidal mineralocorticoid receptor antagonists lower mortality in patients with heart failure and reduced ejection fraction (HFrEF), but more data are needed about nonsteroidal mineralocorticoid ...

Javed Butler, MD, MPH, MBA, discusses the current mineralocorticoid receptor antagonists (MRAs) used for heart failure (HF) with midrange ejection fraction (EF) and HF with preserved EF ...

Catheter ablation is associated with significant reductions in AF symptoms, AF-related hospitalization, and HF symptoms across HF subtypes.

Most of our top stories this month stemmed from the ESC Congress—a mix of drug and device trials as well as guidelines.

Copyright: © 2024 The Author(s). Published by Elsevier Ltd.

Introduction: Heart failure with preserved ejection fraction (HFpEF) presents a unique challenge in cardiology due to its diverse etiology and clinical presentation. Our study introduces a ...

In patients with heart failure (HF) and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF), finerenone had a significantly lower rate of worsening HF events and cardiovascular-related death ...